JP2016530239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530239A5 JP2016530239A5 JP2016525434A JP2016525434A JP2016530239A5 JP 2016530239 A5 JP2016530239 A5 JP 2016530239A5 JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016530239 A5 JP2016530239 A5 JP 2016530239A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- clostridium cluster
- bacteria
- butyrate
- flagellin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 20
- 241000193403 Clostridium Species 0.000 claims 15
- 241000894006 Bacteria Species 0.000 claims 12
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 5
- 108010040721 Flagellin Proteins 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000002708 enhancing effect Effects 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 210000005027 intestinal barrier Anatomy 0.000 claims 5
- 230000007358 intestinal barrier function Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000004666 short chain fatty acids Chemical class 0.000 claims 2
- 101710151190 Flagellin A Chemical class 0.000 claims 1
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 claims 1
- 101150103290 Hcar2 gene Proteins 0.000 claims 1
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- WFVFQUPBGWFLMB-DVYMNCLGSA-N [(3ar,5r,6s,6ar)-5-[(1r)-1,2-dihydroxyethyl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl] butanoate Chemical compound O1C(C)(C)O[C@@H]2[C@@H](OC(=O)CCC)[C@@H]([C@H](O)CO)O[C@@H]21 WFVFQUPBGWFLMB-DVYMNCLGSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000021391 short chain fatty acids Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844204P | 2013-07-09 | 2013-07-09 | |
| US61/844,204 | 2013-07-09 | ||
| PCT/US2014/045801 WO2015006355A2 (en) | 2013-07-09 | 2014-07-08 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019092447A Division JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530239A JP2016530239A (ja) | 2016-09-29 |
| JP2016530239A5 true JP2016530239A5 (https=) | 2017-08-17 |
Family
ID=52280706
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525434A Pending JP2016530239A (ja) | 2013-07-09 | 2014-07-08 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| JP2019092447A Pending JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019092447A Pending JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US9764019B2 (https=) |
| EP (1) | EP3019181A4 (https=) |
| JP (2) | JP2016530239A (https=) |
| WO (1) | WO2015006355A2 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| EP3424515A3 (en) | 2010-08-04 | 2019-06-19 | Thomas Julius Borody | Stool collection devices and methods for using them |
| US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| ES2993669T3 (en) * | 2011-12-01 | 2025-01-03 | Univ Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2015006355A2 (en) | 2013-07-09 | 2015-01-15 | Puretech Ventures, Llc | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| CN105916500A (zh) | 2013-11-27 | 2016-08-31 | 欧洲筛选有限公司 | 用于治疗炎性疾病的化合物、药物组合物和方法 |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| AR103260A1 (es) | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | Modulación inmunitaria |
| US10231941B2 (en) | 2015-01-23 | 2019-03-19 | Temple University—Of The Commonwealth System of Higher Educaton | Use of short chain fatty acids in cancer prevention |
| BR112017024264B1 (pt) | 2015-05-14 | 2022-07-12 | Crestovo Holdings Llc | Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração |
| KR102534545B1 (ko) | 2015-05-22 | 2023-05-18 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법 |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| CN108513545B (zh) | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| ME03487B (me) | 2016-03-04 | 2020-01-20 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CA3226196A1 (en) | 2016-06-14 | 2017-12-21 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| KR102646764B1 (ko) * | 2017-01-27 | 2024-03-13 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도 |
| EP3606325B1 (en) | 2017-04-03 | 2024-09-04 | Gusto Global, LLC | Rational design of microbial-based biotherapeutics |
| EP3606541A1 (en) | 2017-04-05 | 2020-02-12 | Crestovo Holdings LLC | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| JP7136807B2 (ja) | 2017-04-17 | 2022-09-13 | ザ・ユニバーシティ・オブ・シカゴ | ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料 |
| DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| JP2020521760A (ja) | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
| SMT202000695T1 (it) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| DE102017115819A1 (de) * | 2017-07-13 | 2019-01-17 | Aiden Haghikia | Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson |
| JP2020530494A (ja) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 健康な腸バリアを維持及び回復するための組成物及び方法 |
| US12109249B2 (en) | 2018-01-30 | 2024-10-08 | University Of Louisville Research Foundation | Compositions and methods for treating inflammation and cancer |
| CA3102404A1 (en) | 2018-06-05 | 2019-12-12 | Flagship Pioneering Innovations V, Inc. | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| AU2019321681A1 (en) | 2018-08-17 | 2021-02-25 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| EP3856212A1 (en) | 2018-09-27 | 2021-08-04 | Finch Therapeutics Holdings LLC | Compositions and methods for treating epilepsy and related disorders |
| WO2020071463A1 (ja) * | 2018-10-04 | 2020-04-09 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| EP3999029A4 (en) * | 2019-07-17 | 2023-07-26 | University of Utah Research Foundation | CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATMENT OF OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL |
| PH12021553137A1 (en) | 2019-07-19 | 2022-07-25 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
| US20220364056A1 (en) * | 2019-09-25 | 2022-11-17 | Philipps-Universität Marburg | Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy |
| US12397563B2 (en) | 2023-08-24 | 2025-08-26 | Stolle Machinery Company, Llc | Automatic label creator and method for can decorating |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2383662A1 (fr) | 1977-03-15 | 1978-10-13 | Cassenne Lab Sa | Nouvelles compositions a usage cosmetique |
| DE3069074D1 (en) | 1979-11-16 | 1984-10-04 | Sterosynt Ltd | 6-alpha-9-alpha-difluoro-16-beta-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them |
| US5569680A (en) | 1995-02-13 | 1996-10-29 | Trustees Of The Univ. Of Penna | Method of treating inflammatory bowel disease with tributyrin |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| US7094555B2 (en) * | 2001-04-05 | 2006-08-22 | Benaroya Research Institute At Virginia Mason | Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment |
| EP1743654A1 (en) * | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| GB0903016D0 (en) * | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| WO2015006355A2 (en) * | 2013-07-09 | 2015-01-15 | Puretech Ventures, Llc | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
-
2014
- 2014-07-08 WO PCT/US2014/045801 patent/WO2015006355A2/en not_active Ceased
- 2014-07-08 EP EP14822228.4A patent/EP3019181A4/en not_active Ceased
- 2014-07-08 JP JP2016525434A patent/JP2016530239A/ja active Pending
- 2014-07-08 US US14/903,377 patent/US9764019B2/en active Active
-
2017
- 2017-08-18 US US15/680,629 patent/US10130695B2/en not_active Expired - Fee Related
-
2018
- 2018-10-15 US US16/160,869 patent/US20190134179A1/en not_active Abandoned
-
2019
- 2019-05-15 JP JP2019092447A patent/JP2019189609A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530239A5 (https=) | ||
| Iacob et al. | Infectious threats, the intestinal barrier, and its trojan horse: dysbiosis | |
| Peloquin et al. | Mechanisms of pediatric inflammatory bowel disease | |
| Chervy et al. | Adherent-Invasive E. coli: Update on the Lifestyle of a Troublemaker in Crohn’s Disease | |
| Huang et al. | Skin manifestations of inflammatory bowel disease | |
| Miehlke et al. | Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis | |
| Burke et al. | Modifiable environmental factors in inflammatory bowel disease | |
| JP2019189609A (ja) | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 | |
| Doyle et al. | Eosinophils in eosinophilic esophagitis: the road to fibrostenosis is paved with good intentions | |
| CY1122626T1 (el) | Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα | |
| JP2015517489A5 (https=) | ||
| JP2015517488A5 (https=) | ||
| JP2018505882A5 (https=) | ||
| JP2012515213A5 (https=) | ||
| Steinert et al. | Gastro-intestinal tract: The leading role of mucosal immunity | |
| JP2015522630A5 (https=) | ||
| Opoku et al. | Intestinal microbiome–rheumatoid arthritis crosstalk: The therapeutic role of probiotics | |
| Salvadori et al. | Microbiota, renal disease and renal transplantation | |
| JP2017533220A5 (https=) | ||
| Zhong et al. | Bacteroides fragilis capsular polysaccharide A ameliorates ulcerative colitis in rat by recovering intestinal barrier integrity and restoring gut microbiota | |
| Kou et al. | Systemic dysregulation of the gut microenvironment plays a pivotal role in the onset and progression of inflammatory bowel disease | |
| JP2017519763A5 (https=) | ||
| Qian et al. | Exploring the etiology of colitis: insights from gut microbiota research | |
| Wasim et al. | Microbial imbalance in the gut: a new frontier in Rheumatoid arthritis research | |
| Azzman | Crohn’s disease: Potential drugs for modulation of autophagy |